KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) CFO Mary Reumuth sold 1,706 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $13,016.78. Following the transaction, the chief financial officer now owns 68,581 shares in the company, valued at approximately $523,273.03. The trade was a 2.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
KALA BIO Stock Up 2.1 %
KALA stock opened at $7.69 on Wednesday. The company has a market cap of $35.45 million, a PE ratio of -0.62 and a beta of -2.11. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO, Inc. has a 52 week low of $4.21 and a 52 week high of $9.25. The business has a 50-day simple moving average of $6.71 and a 200 day simple moving average of $6.32.
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings | Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
KALA BIO (NASDAQ:KALA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping analysts' consensus estimates of ($2.43) by $0.50. Sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.
Institutional Investors Weigh In On KALA BIO
A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 443,661 shares of the company's stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP's holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of KALA BIO in a research report on Friday, November 15th.
Get Our Latest Research Report on KALA BIO
About KALA BIO
(
Get Free Report)
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
